Vertex is to acquire Alpine Immune Sciences for just under $5bn, in a move that will boost its presence in kidney disease, and potentially open it up to a range of autoimmune diseases.
Vertex’s $5bn Alpine Buyout Builds Autoimmune Disease Presence
The company hopes for a “Humira-like” blockbuster with povetacicept, the object of the sector’s biggest M&A deal so far this year.
